MCID: PNC041
MIFTS: 51

Pancreatic Ductal Adenocarcinoma

Categories: Cancer diseases, Endocrine diseases

Aliases & Classifications for Pancreatic Ductal Adenocarcinoma

MalaCards integrated aliases for Pancreatic Ductal Adenocarcinoma:

Name: Pancreatic Ductal Adenocarcinoma 12 15 17 70
Ductal Adenocarcinoma of the Pancreas 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3498
NCIt 50 C9120
SNOMED-CT 67 792907004
UMLS 70 C1335302

Summaries for Pancreatic Ductal Adenocarcinoma

Disease Ontology : 12 A pancreatic adenocarcinoma that derives from pancreatic duct cells.

MalaCards based summary : Pancreatic Ductal Adenocarcinoma, also known as ductal adenocarcinoma of the pancreas, is related to pancreatic cancer and cholangiocarcinoma, and has symptoms including abdominal pain, pruritus and icterus. An important gene associated with Pancreatic Ductal Adenocarcinoma is MIR155 (MicroRNA 155), and among its related pathways/superpathways is LncRNA-mediated mechanisms of therapeutic resistance. The drugs Pancrelipase and Paclitaxel have been mentioned in the context of this disorder. Affiliated tissues include Pancreas, lymph node and t cells.

Related Diseases for Pancreatic Ductal Adenocarcinoma

Diseases related to Pancreatic Ductal Adenocarcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 260)
# Related Disease Score Top Affiliating Genes
1 pancreatic cancer 32.6 UCA1 PVT1 MIR21 MIR155 MALAT1 HOTTIP
2 cholangiocarcinoma 31.6 UCA1 MIR21 MALAT1 H19 AFAP1-AS1
3 lung cancer susceptibility 3 31.1 MIR31HG MIR21 MALAT1 HOTAIR H19 AFAP1-AS1
4 retinitis pigmentosa 11 30.9 UCA1 PVT1 HOTAIR
5 kidney cancer 30.9 PVT1 MIR21 MALAT1 HOTAIR H19
6 b-cell lymphoma 30.9 PVT1 MIR21 MIR155 MALAT1 HOTAIR
7 glioblastoma 30.9 TUSC7 MIR21 MIR155 MALAT1 HOTAIRM1 HOTAIR
8 gallbladder cancer 30.7 UCA1 PVT1 MALAT1 HOTAIR H19 AFAP1-AS1
9 renal cell carcinoma, nonpapillary 30.7 UCA1 PVT1 MIR21 MIR155 MALAT1 HOTAIR
10 small cell cancer of the lung 30.6 MIR21 MALAT1 HOTTIP HOTAIR
11 osteogenic sarcoma 30.6 UCA1 TUSC7 PVT1 MALAT1 HOTTIP HOTAIR
12 gastrointestinal system cancer 30.6 MIR21 MIR155 MALAT1 HOTAIR H19
13 nasopharyngeal carcinoma 30.5 PVT1 MIR21 MALAT1 HOTAIR H19 AFAP1-AS1
14 leukemia, acute myeloid 30.5 UCA1 TUSC7 MIR21 MIR155 MALAT1 HOTAIRM1
15 bladder cancer 30.5 UCA1 PVT1 MIR31HG MIR21 MALAT1 HOTAIR
16 clear cell renal cell carcinoma 30.4 PVT1 MIR21 MIR155 MALAT1
17 esophageal cancer 30.4 UCA1 PVT1 MIR21 MALAT1 HOTTIP HOTAIR
18 hepatocellular carcinoma 30.3 UCA1 TUSC7 PVT1 MIR21 MIR155 MALAT1
19 pituitary adenoma 30.3 MALAT1 HOTAIR H19
20 lung cancer 30.1 UCA1 TUSC7 PVT1 MIR31HG MIR21 MIR155
21 gastric cancer 30.0 UCA1 TUSC7 TMEM238L PVT1 MIR31HG MIR21
22 colorectal cancer 29.9 UCA1 TUSC7 TMEM238L PVT1 MIR31HG MIR21
23 adenocarcinoma 11.4
24 pancreatic cancer 5 11.2
25 pancreatic adenocarcinoma 11.1
26 pancreatitis 10.9
27 pancreas disease 10.7
28 pancreatic agenesis 1 10.7
29 autoimmune pancreatitis 10.7
30 pancreatic ductal carcinoma 10.7
31 intrahepatic cholangiocarcinoma 10.6
32 severe combined immunodeficiency 10.6
33 47,xyy 10.6
34 hypoxia 10.6
35 neutropenia 10.5
36 obstructive jaundice 10.5
37 pancreatitis, hereditary 10.5
38 neuroendocrine tumor 10.5
39 acute pancreatitis 10.5
40 adenosquamous carcinoma 10.5
41 body mass index quantitative trait locus 11 10.4
42 body mass index quantitative trait locus 9 10.4
43 body mass index quantitative trait locus 8 10.4
44 body mass index quantitative trait locus 4 10.4
45 body mass index quantitative trait locus 10 10.4
46 body mass index quantitative trait locus 7 10.4
47 body mass index quantitative trait locus 12 10.4
48 body mass index quantitative trait locus 14 10.4
49 body mass index quantitative trait locus 18 10.4
50 body mass index quantitative trait locus 19 10.4

Graphical network of the top 20 diseases related to Pancreatic Ductal Adenocarcinoma:



Diseases related to Pancreatic Ductal Adenocarcinoma

Symptoms & Phenotypes for Pancreatic Ductal Adenocarcinoma

UMLS symptoms related to Pancreatic Ductal Adenocarcinoma:


abdominal pain; pruritus; icterus

Drugs & Therapeutics for Pancreatic Ductal Adenocarcinoma

Drugs for Pancreatic Ductal Adenocarcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 122)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Pancrelipase Approved, Investigational Phase 3 53608-75-6
2
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
3
Gemcitabine Approved Phase 3 95058-81-4 60750
4
Hyaluronic acid Approved, Vet_approved Phase 3 9004-61-9 53477741
5 pancreatin Phase 3
6 Folfirinox Phase 3
7 glucocorticoids Phase 3
8 Antimitotic Agents Phase 3
9 Immunosuppressive Agents Phase 3
10 Albumin-Bound Paclitaxel Phase 3
11 Tubulin Modulators Phase 3
12 Anti-Infective Agents Phase 3
13 Antiviral Agents Phase 3
14 Antimetabolites Phase 3
15 Immunologic Factors Phase 3
16 Protein Kinase Inhibitors Phase 3
17 N-(cyanomethyl)-4-(2-((4-(4-morpholinyl)phenyl)amino)-4-pyrimidinyl)benzamide Phase 3
18
Pemetrexed Approved, Investigational Phase 1, Phase 2 150399-23-8, 137281-23-3 446556 60843
19
Carboplatin Approved Phase 1, Phase 2 41575-94-4 10339178 498142 38904
20
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
21
nivolumab Approved Phase 1, Phase 2 946414-94-4
22
Dimethyl sulfoxide Approved, Vet_approved Phase 2 67-68-5 679
23
Chlorambucil Approved Phase 2 305-03-3 2708
24
Niraparib Approved, Investigational Phase 2 1038915-60-4 24958200
25
Romidepsin Approved, Investigational Phase 1, Phase 2 128517-07-7 5352062
26
Azacitidine Approved, Investigational Phase 1, Phase 2 320-67-2 9444
27
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
28
Bevacizumab Approved, Investigational Phase 1, Phase 2 216974-75-3
29
Cisplatin Approved Phase 2 15663-27-1 84093 441203 2767
30
Pembrolizumab Approved Phase 2 1374853-91-4
31
Coal tar Approved Phase 1, Phase 2 8007-45-2
32
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
33
Tegafur Approved, Investigational Phase 2 17902-23-7 5386
34
Olaparib Approved Phase 2 763113-22-0 23725625
35
Atezolizumab Approved, Investigational Phase 2 1380723-44-3
36
Tremelimumab Investigational Phase 2 745013-59-6
37 Folic Acid Antagonists Phase 1, Phase 2
38
Liposomal doxorubicin Phase 2 31703
39 Alkylating Agents Phase 2
40 Pharmaceutical Solutions Phase 2
41 Anti-Bacterial Agents Phase 1, Phase 2
42 pyruvate Phase 2
43 Angiogenesis Inhibitors Phase 1, Phase 2
44 Antibiotics, Antitubercular Phase 1, Phase 2
45 Immunotoxins Phase 1, Phase 2
46 Micronutrients Phase 1, Phase 2
47 Trace Elements Phase 1, Phase 2
48 Nutrients Phase 1, Phase 2
49 Vitamins Phase 1, Phase 2
50 Protective Agents Phase 1, Phase 2

Interventional clinical trials:

(show top 50) (show all 160)
# Name Status NCT ID Phase Drugs
1 PAXG Out in the Country Recruiting NCT04480268 Phase 4 PAXG regimen (cisplatin, nab-paclitaxel, capecitabine, gemcitabine) chemotherapy
2 Prevention of Upper Gastrointestinal Hemorrhage Using Albis® in the Patients of Locally Advanced Pancreatic Cancer Who Underwent Concurrent Chemoradiotherapy Withdrawn NCT02570529 Phase 4 Albis®;Placebo
3 A Phase 3 Study of Relacorilant in Combination With Nab-Paclitaxel in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (RELIANT) Active, not recruiting NCT04329949 Phase 3 Relacorilant, 100 mg and 25 mg;Nab paclitaxel
4 A Phase III Randomized Study Evaluating Gemcitabine and Paclitaxel Versus Gemcitabine Alone After FOLFIRINOX Failure or Intolerance in Metastatic Pancreatic Ductal Adenocarcinoma Active, not recruiting NCT03943667 Phase 3 Gemcitabine;Paclitaxel
5 Mesenteric Approach vs. Conventional Approach for Pancreatic Cancer During Pancreaticoduodenectomy (MAPLE-PD Trial) Not yet recruiting NCT03317886 Phase 3
6 A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Gemcitabine and Nab-paclitaxel Combined With Momelotinib in Subjects With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Preceded by a Dose-finding, Lead-in Phase Terminated NCT02101021 Phase 3 Momelotinib;Placebo to match momelotinib;Nab-paclitaxel;Gemcitabine
7 A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of PEGylated Recombinant Human Hyaluronidase (PEGPH20) in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Subjects With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma Terminated NCT02715804 Phase 3 Placebo;nab-Paclitaxel;Gemcitabine
8 Phase 2 Study Evaluating the Efficacy,Safety,Tolerability and PK of siG12D-LODER in the Treatment of Patients With Unresectable LAPC When Used in Conjunction With Standard Chemotherapy (Gemcitabine+Nab-Paclitaxel) Versus Chemotherapy Alone Unknown status NCT01676259 Phase 2 siG12D-LODER;Gemcitabine+nab-Paclitaxel
9 The Effects of Neoadjuvant Metformin on Tumour Cell Proliferation and Tumour Progression in Pancreatic Ductal Adenocarcinoma Unknown status NCT02978547 Phase 2 Metformin Hydrochloride 500Mg Tablet
10 A Phase 1/2, Open-Label, Safety, Tolerability, and Efficacy Study of Epacadostat in Combination With Pembrolizumab and Chemotherapy in Subjects With Advanced or Metastatic Solid Tumors (ECHO-207/KEYNOTE-723) Completed NCT03085914 Phase 1, Phase 2 Epacadostat;Pembrolizumab;Oxaliplatin;Leucovorin;5-Fluorouracil;Gemcitabine;nab-Paclitaxel;Carboplatin;Paclitaxel;Pemetrexed;Cyclophosphamide;Carboplatin;Cisplatin;5-Fluorouracil;Investigator's choice of platinum agent
11 A Multicenter, Open-Label Pilot Phase 2 Study to Investigate the Preliminary Efficacy and Safety of INNO-206 (Doxorubicin-EMCH) in Subjects With Advanced or Unresectable Pancreatic Ductal Carcinoma Whose Tumors Have Progressed Following Prior Treatment With Gemcitabine and Fluoropyrimidine-Based Chemotherapy Completed NCT01580397 Phase 2 INNO-206
12 A Phase II Open-Label, Multi-Center Study of MEDI4736 Evaluated as Single Agent or in Combination With Tremelimumab in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02558894 Phase 2 MEDI4736 monotherapy;tremelimumab+MEDI4736
13 A Phase Ib and II Open-Label, Multi-Center Study of MEDI4736 Evaluated in Different Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02583477 Phase 1, Phase 2 MEDI4736 in combination with nab-paclitaxel and gemcitabine;MEDI4736 in combination with AZD5069
14 Modified FOLFIRINOX for Gemcitabine Refractory Pancreatic Cancer: A Phase II Multicenter Trial Completed NCT02440958 Phase 2 modified FOLFIRINOX regimen
15 An Adaptive, Open-Label, Randomized Phase 2 Study of Abemaciclib as a Monotherapy and in Combination With Other Agents Versus Choice of Standard of Care (Gemcitabine or Capecitabine) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02981342 Phase 2 Abemaciclib;LY3023414;Gemcitabine;Capecitabine
16 Randomised Phase II Trial to Investigate Two Different Schedules of Nab-paclitaxel (Abraxane) Combined With Gemcitabine as First Line Treatment for Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT03529175 Phase 2 Abraxane (nab-paclitaxel);Gemcitabine
17 A 3-Arm Phase 2 Double-Blind Randomized Study of Gemcitabine, Abraxane® Plus Placebo Versus Gemcitabine, Abraxane® Plus 1 or 2 Truncated Courses of Demcizumab in Subjects With 1st-Line Metastatic Pancreatic Ductal Adenocarcinoma Completed NCT02289898 Phase 2 Demcizumab;Abraxane®;gemcitabine;Placebo
18 A Phase 1b/2 Pilot Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine (Nabplagem) in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma (PDA) Completed NCT01893801 Phase 1, Phase 2 nab-paclitaxel;Cisplatin;gemcitabine
19 A Phase I/II Trial of Combination Immunotherapy With Nivolumab and a CCR2/CCR5 Dual Antagonist (BMS-813160) With or Without GVAX Following Chemotherapy and Radiotherapy for Locally Advanced Pancreatic Ductal Adenocarcinomas (PDACs). Recruiting NCT03767582 Phase 1, Phase 2 Nivolumab;CCR2/CCR5 dual antagonist;GVAX
20 A Randomized Phase II Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting NCT03727880 Phase 2 Pembrolizumab;Defactinib
21 An International Multicentre, Open-Label First in Human Phase I/II Study to Evaluate the Safety, Tolerability, Biodistribution and Antitumour Activity of 177Lu-3BP-227 for the Treatment of Subjects With Solid Tumours Expressing Neurotensin Receptor 1 Recruiting NCT03525392 Phase 1, Phase 2 177Lu-3BP-227 (also called 177Lu-IPN01087)
22 A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC) Recruiting NCT04390763 Phase 2 gemcitabine;nab-paclitaxel
23 A Phase 2 Study to Evaluate the Safety and Efficacy of Nab-pacliatxel Plus Gemcitabine in Korean Patients With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02426281 Phase 2 nab-paclitaxel;gemcitabine
24 A Phase I/II Study to Evaluate the Tolerability and Efficacy of BMS-813160 (CCR2/5 Inhibitor) With Nivolumab and Gemcitabine and Nab-paclitaxel in Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting NCT03496662 Phase 1, Phase 2 BMS-813160;Nivolumab;Gemcitabine;Nab-paclitaxel
25 A Phase II Pilot Trial of Nivolumab + Albumin-Bound Paclitaxel + Paricalcitol + Cisplatin + Gemcitabine (NAPPCG) In Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT02754726 Phase 2 Nivolumab;Albumin-bound paclitaxel;Paricalcitol;Cisplatin;Gemcitabine
26 A Randomized Non-comparative Phase II Study of Maintenance Therapy With OSE2101 Vaccine Alone or in Combination With Nivolumab, or FOLFIRI After Induction Therapy With FOLFIRINOX in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (TEDOPaM - D17-01 PRODIGE 63 Study). Recruiting NCT03806309 Phase 2 FOLFIRI;OSE2101;Nivolumab
27 Phase II Study of PEGPH20 and Pembrolizumab (MK-3475) for Patients With Previously Treated Hyaluronan High (HA-High) Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03634332 Phase 2 PEGPH20
28 An Open-label, Multi-center, Phase 1b Study to Investigate the Safety and Tolerability of SLC-0111 (WBI-5111) in Combination With Gemcitabine in Metastatic Pancreatic Ductal Adenocarcinoma Subjects Positive for Carbonic Anhydrase IX Recruiting NCT03450018 Phase 1, Phase 2 SLC-0111;Gemcitabine Injection
29 Transabdominal Ultrasound With BR55 for Characterization of Pancreatic Lesions Recruiting NCT03486327 Phase 2 BR55
30 A Pilot Study of Chlorambucil in Pre-treated Metastatic Pancreatic Adenocarcinoma Patients Bearing a Germ Line BRCA or Other DNA Defects Repair (DDR) Mutations. Recruiting NCT04692740 Phase 2 Chlorambucil, Oral, 2 Mg
31 Randomized Phase II Trial of Two Different Nutritional Approaches for Patients Receiving Treatment for Their Advanced Pancreatic Cancer Recruiting NCT04631445 Phase 2
32 A Phase II Trial to Assess the Evolution of KRAS Mutation Load by Liquid Biopsy in Patients With Resectable Pancreatic Ductal Adenocarcinoma Treated With Neoadjuvant NALIRINOX Recruiting NCT04010552 Phase 2 NALRINOX combination
33 A Phase 2 Trial to Evaluate the Safety and Antitumor Activity of Pembrolizumab and OLApaRib (POLAR) Maintenance for Patients With Metastatic Pancreatic Ductal Adenocarcinoma and Homologous Recombination Deficiency and/or Exceptional Treatment Response to Platinum-Based Therapy Recruiting NCT04666740 Phase 2 Pembrolizumab;Olaparib
34 Phase II Study of Neoadjuvant Chemotherapy of Gemcitabine+Nab-paclitaxel Therapy for Patients With Borderline Resectable Pancreatic Cancer Recruiting NCT02926183 Phase 2 Neoadjuvant chemotherapy of gemcitabine plus nab-paclitaxel
35 A Phase 2A, Dose-Finding Study of Ad5.F35-hGCC-PADRE Vaccine in Adults With Gastrointestinal Adenocarcinomas at Risk of Relapse Post Definitive Surgery and Standard Therapy Recruiting NCT04111172 Phase 2
36 A Phase II Trial of Nab-Paclitaxel Plus Cisplatin Plus Gemcitabine in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03915444 Phase 2 nab-Paclitaxel + Cisplatin + Gemcitabine
37 Phase II Study of Niraparib and TSR-042 in Patients With Germline or Somatic BRCA1/2 and PALB2-Related Pancreatic Cancer Recruiting NCT04493060 Phase 2 Niraparib
38 Impact of Tumor and Stromal Subtypes on Efficacy of Neoadjuvant FOLFIRINOX in Subjects With Non-Metastatic Pancreatic Cancer Recruiting NCT03977233 Phase 2 Oxaliplatin;Leucovorin;Irinotecan Hydrochloride;5-FU
39 Hyperpolarized 13C Pyruvate MRI for Treatment Response Assessment in Pancreatic Ductal Adenocarcinoma Recruiting NCT04565327 Phase 2 Hyperpolarized Carbon C 13 Pyruvate
40 A Health Service Research Study to Investigate Survival of Metastatic Pancreatic Cancer Patients After Sequential Chemotherapy: An AIO Phase II Cross Over Trial (PANTHEON) Recruiting NCT03331640 Phase 2 OFF;FOLFIRI Protocol
41 A Multicenter, Phase I/II Study of Sequential Epigenetic and Immune Targeting in Combination With Nab-Paclitaxel/Gemcitabine in Patients With Advanced Pancreatic Ductal Adenocarcinoma. Recruiting NCT04257448 Phase 1, Phase 2 Romidepsin;Azacitidine;nab-Paclitaxel;Gemcitabine;Durvalumab;Lenalidomide capsule
42 A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT03611556 Phase 1, Phase 2
43 PRIMUS002: An Umbrella Phase II Study Examining Two Neo-adjuvant Regimens (FOLFOX-A and AG) in Resectable and Borderline Resectable Pancreatic Ductal AdenoCarcinoma (PDAC), Focusing on Biomarker and Liquid Biopsy Development Recruiting NCT04176952 Phase 2 FOLFOX-A;AG
44 Multi-center, Open-label, Phase 1b Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel Recruiting NCT03666832 Phase 1, Phase 2 TEW-7197
45 A Randomized Phase II Trial of Short-course Versus Long-course Pre-operative Chemotherapy With mFOLFIRINOX or PAXG Regimen for Stage I-III Pancreatic Ductal Adenocarcinoma (PDAC) Recruiting NCT04793932 Phase 2 PAXG;mFOLFIRINOX;short-course chemotherapy;long-course chemotherapy
46 Ultrasound-enhanced Uptake of Chemotherapy in Patients With Inoperable Pancreatic Ductal Adenocarcinoma - A Randomized Controlled Trial Recruiting NCT04146441 Phase 2 Chemotherapy
47 A Phase II Pilot Trial Of Paclitaxel Protein Bound and Gemcitabine Based Chemotherapy and the Addition Of Paricalcitol Upon Attainment of Stable or Progressive Disease in Patients With Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma Recruiting NCT04054362 Phase 2 Paclitaxel protein bound;Cisplatin;Gemcitabine;Paricalcitol
48 A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) Recruiting NCT03193190 Phase 1, Phase 2 Nab-Paclitaxel;Gemcitabine;Oxaliplatin;Leucovorin;Fluorouracil;Atezolizumab;Cobimetinib;PEGPH20;BL-8040;Selicrelumab;Bevacizumab;RO6874281;AB928;Tiragolumab;Tocilizumab
49 Prospective Randomized Multicenter Phase II Trial to Investigate Intensified Neoadjuvant Chemotherapy in Locally Advanced Pancreatic Cancer Active, not recruiting NCT02125136 Phase 2 Gem/nab-Pac;FOLFIFINOX
50 A Phase II Study of Neoadjuvant FOLFIRINOX in Patients With Resectable Pancreatic Ductal Adenocarcinoma With Tissue Collection Active, not recruiting NCT02178709 Phase 2 FOLFIRINOX

Search NIH Clinical Center for Pancreatic Ductal Adenocarcinoma

Genetic Tests for Pancreatic Ductal Adenocarcinoma

Anatomical Context for Pancreatic Ductal Adenocarcinoma

MalaCards organs/tissues related to Pancreatic Ductal Adenocarcinoma:

40
Pancreas, Lymph Node, T Cells, Neutrophil, Liver, Myeloid, Endothelial
LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database

Cells/anatomical compartments in embryo or adult related to Pancreatic Ductal Adenocarcinoma:
# Tissue Anatomical CompartmentCell Relevance
1 Pancreas Pancreatic Ducts Affected by disease

Publications for Pancreatic Ductal Adenocarcinoma

Articles related to Pancreatic Ductal Adenocarcinoma:

(show top 50) (show all 9398)
# Title Authors PMID Year
1
Knockdown of microRNA-21 inhibits proliferation and increases cell death by targeting programmed cell death 4 (PDCD4) in pancreatic ductal adenocarcinoma. 61 47
21088996 2011
2
MicroRNA expression analyses in preoperative pancreatic juice samples of pancreatic ductal adenocarcinoma. 47 61
21068491 2010
3
MicroRNA-21 is induced early in pancreatic ductal adenocarcinoma precursor lesions. 47 61
20093556 2010
4
MicroRNAs in plasma of pancreatic ductal adenocarcinoma patients as novel blood-based biomarkers of disease. 47 61
19723895 2009
5
Analysis of microRNAs in pancreatic fine-needle aspirates can classify benign and malignant tissues. 61 47
18719196 2008
6
MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. 61 47
17237814 2007
7
Elevated expression of microRNAs 155, 203, 210 and 222 in pancreatic tumors is associated with poorer survival. 47
19551852 2010
8
Long intergenic non-protein coding RNA 960 regulates cancer cell viability, migration and invasion through modulating miR-146a-5p/interleukin 1 receptor associated kinase 1 axis in pancreatic ductal adenocarcinoma. 61
33380238 2021
9
Pancreatic cancer is marked by complement-high blood monocytes and tumor-associated macrophages. 61
33782087 2021
10
Use of ring-enhancement and focal necrosis to differentiate pancreatic adenosquamous carcinoma from pancreatic ductal adenocarcinoma on CT and MRI. 61
33387918 2021
11
Poly(ADP-ribose) polymerase inhibition in pancreatic cancer. 61
33341987 2021
12
Pancreatic Cancer-Associated Diabetes is Clinically Distinguishable From Conventional Diabetes. 61
33453685 2021
13
Promising role of long non-coding RNA PCAT6 in malignancies. 61
33761616 2021
14
The Cell Line-Dependent Diversity in Initial Morphological Dynamics of Pancreatic Cancer Cell Peritoneal Metastasis Visualized by an Artificial Human Peritoneal Model. 61
33493887 2021
15
Impact of Margin Status on Survival in Patients with Pancreatic Ductal Adenocarcinoma Receiving Neoadjuvant Chemotherapy. 61
33338577 2021
16
CREPT serves as a biomarker of poor survival in pancreatic ductal adenocarcinoma. 61
33125631 2021
17
Modified Appleby Procedure, Distal Splenopancreatectomy with Celiac Axis Resection. 61
33084990 2021
18
Envisioning the immune system to determine its role in pancreatic ductal adenocarcinoma: Culprit or victim? 61
33647329 2021
19
Single-Pass vs 2-Pass Endoscopic Ultrasound-Guided Fine-Needle Biopsy Sample Collection for Creation of Pancreatic Adenocarcinoma Organoids. 61
32119924 2021
20
Human splenic TER cells: A relevant prognostic factor acting via the artemin-GFRα3-ERK pathway in pancreatic ductal adenocarcinoma. 61
33236361 2021
21
Peritoneal Lavage Tumor DNA as a Novel Biomarker for Predicting Peritoneal Recurrence in Pancreatic Ductal Adenocarcinoma. 61
32875467 2021
22
Neoadjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma is Associated with Lower Post-Pancreatectomy Readmission Rates: A Population-Based Cohort Study. 61
33398644 2021
23
Defining a minimum number of examined lymph nodes improves the prognostic value of lymphadenectomy in pancreas ductal adenocarcinoma. 61
32900612 2021
24
FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience. 61
32885350 2021
25
Response to radiotherapy in pancreatic ductal adenocarcinoma is enhanced by inhibition of myeloid-derived suppressor cells using STAT3 anti-sense oligonucleotide. 61
33097963 2021
26
The role of intraperitoneal chemotherapy in the surgical management of pancreatic ductal adenocarcinoma: a systematic review. 61
33486670 2021
27
Chemopreventive Agents After Pancreatic Resection for Ductal Adenocarcinoma: Legend or Scientific Evidence? 61
32920722 2021
28
Plasma protein biomarkers for early detection of pancreatic ductal adenocarcinoma. 61
33411965 2021
29
Ubiquitin-specific protease 14 (USP14) promotes proliferation and metastasis in pancreatic ductal adenocarcinoma. 61
33394290 2021
30
Comparative modeling and structure based drug repurposing of PAX2 transcription factor for targeting acquired chemoresistance in pancreatic ductal adenocarcinoma. 61
32174259 2021
31
Impact of Neoadjuvant Chemotherapy and Pretreatment Biliary Drainage for Pancreatic Head Ductal Adenocarcinoma. 61
33811566 2021
32
miR-365 secreted from M2 Macrophage-derived extracellular vesicles promotes pancreatic ductal adenocarcinoma progression through the BTG2/FAK/AKT axis. 61
33811437 2021
33
Unfolding antifungals: as a new foe to pancreatic ductal adenocarcinoma-a mini-review. 61
33796989 2021
34
Factors associated with missed and misinterpreted cases of pancreatic ductal adenocarcinoma. 61
32997176 2021
35
Intra-pancreatic distal cholangiocarcinoma and pancreatic ductal adenocarcinoma: a common short and long-term prognosis? 61
33486711 2021
36
Downregulation of ZNF395 Drives Progression of Pancreatic Ductal Adenocarcinoma through Enhancement of Growth Potential. 61
33794543 2021
37
Clinical Characteristics of Patients With Pancreatic Cancer and Pathogenic ATM Alterations. 61
33733050 2021
38
Radiographic and Serologic Predictors of Pathologic Major Response to Preoperative Therapy for Pancreatic Cancer. 61
31274655 2021
39
The novel driver gene ASAP2 is a potential druggable target in pancreatic cancer. 61
33605496 2021
40
Inhibition of Hedgehog Signaling Alters Fibroblast Composition in Pancreatic Cancer. 61
33495315 2021
41
3d tissue models as tools for radiotherapy screening for pancreatic cancer. 61
33684308 2021
42
AXL is a key factor for cell plasticity and promotes metastasis in pancreatic cancer. 61
33811159 2021
43
Host Cxcr2-Dependent Regulation of Pancreatic Cancer Growth, Angiogenesis, and Metastasis. 61
33453178 2021
44
MUC4 enhances gemcitabine resistance and malignant behaviour in pancreatic cancer cells expressing cancer-associated short O-glycans. 61
33485947 2021
45
Comparison of endoscopic ultrasound-guided fine-needle biopsy versus fine-needle aspiration for genomic profiling and DNA yield in pancreatic cancer: a randomized crossover trial. 61
32767288 2021
46
Trials and tribulations of pancreatic cancer immunotherapy. 61
33549709 2021
47
Reproducibility of tumor budding assessment in pancreatic cancer based on a multicenter interobserver study. 61
33330964 2021
48
Organoid technology for personalized pancreatic cancer therapy. 61
33492660 2021
49
Genotype-phenotype correlations for pancreatic cancer risk in Dutch melanoma families with pathogenic CDKN2A variants. 61
32482799 2021
50
Time density curve of dynamic contrast-enhanced computed tomography correlates with histological characteristics of pancreatic cancer. 61
33732352 2021

Variations for Pancreatic Ductal Adenocarcinoma

Copy number variations for Pancreatic Ductal Adenocarcinoma from CNVD:

7 (show top 50) (show all 315)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 14616 1 109662726 110421733 Loss Pancreatic ductal adenocarcinoma
2 14979 1 111694621 112653686 Loss Pancreatic ductal adenocarcinoma
3 15141 1 11296895 11700048 Loss Pancreatic ductal adenocarcinoma
4 15254 1 113902673 114772618 Loss Pancreatic ductal adenocarcinoma
5 21071 1 156591077 157602759 Gain Pancreatic ductal adenocarcinoma
6 22927 1 16990962 17780550 Loss Pancreatic ductal adenocarcinoma
7 23665 1 172632928 173462394 Gain Pancreatic ductal adenocarcinoma
8 23983 1 174098656 174792564 Gain Pancreatic ductal adenocarcinoma
9 24268 1 17780550 18767187 Loss Pancreatic ductal adenocarcinoma
10 25340 1 18767187 19870518 Loss Pancreatic ductal adenocarcinoma
11 25429 1 189012940 189640525 Gain Pancreatic ductal adenocarcinoma
12 25525 1 190940606 191897513 Gain Pancreatic ductal adenocarcinoma
13 25603 1 191897513 192833019 Gain Pancreatic ductal adenocarcinoma
14 25668 1 192833019 193928417 Gain Pancreatic ductal adenocarcinoma
15 25957 1 195125528 196179631 Gain Pancreatic ductal adenocarcinoma
16 26123 1 197274194 198251428 Gain Pancreatic ductal adenocarcinoma
17 26286 1 19870518 21264484 Loss Pancreatic ductal adenocarcinoma
18 27649 1 210637543 211466127 Gain Pancreatic ductal adenocarcinoma
19 29512 1 232834654 234059648 Gain Pancreatic ductal adenocarcinoma
20 29988 1 23881482 24596143 Loss Pancreatic ductal adenocarcinoma
21 30783 1 24596143 24901021 Loss Pancreatic ductal adenocarcinoma
22 31049 1 24901021 26202341 Loss Pancreatic ductal adenocarcinoma
23 31229 1 26202341 27453508 Loss Pancreatic ductal adenocarcinoma
24 31475 1 27702974 28279739 Loss Pancreatic ductal adenocarcinoma
25 31649 1 29154418 29949616 Loss Pancreatic ductal adenocarcinoma
26 31710 1 29949616 31202941 Loss Pancreatic ductal adenocarcinoma
27 31822 1 31202941 32179980 Loss Pancreatic ductal adenocarcinoma
28 32104 1 33581730 34569385 Loss Pancreatic ductal adenocarcinoma
29 32211 1 34569385 35804738 Loss Pancreatic ductal adenocarcinoma
30 32498 1 36953732 37599763 Loss Pancreatic ductal adenocarcinoma
31 32649 1 38143717 38830556 Loss Pancreatic ductal adenocarcinoma
32 32759 1 3913633 5229374 Loss Pancreatic ductal adenocarcinoma
33 33297 1 44268667 45000776 Loss Pancreatic ductal adenocarcinoma
34 33745 1 47532872 48556325 Loss Pancreatic ductal adenocarcinoma
35 34094 1 5229374 6509870 Loss Pancreatic ductal adenocarcinoma
36 34199 1 53371440 53750907 Loss Pancreatic ductal adenocarcinoma
37 34230 1 53750907 54788971 Loss Pancreatic ductal adenocarcinoma
38 36948 1 8379388 9142502 Loss Pancreatic ductal adenocarcinoma
39 37455 1 9142502 9661749 Loss Pancreatic ductal adenocarcinoma
40 38508 10 103075332 103271952 Gain Pancreatic ductal adenocarcinoma
41 41307 10 15917593 17007248 Gain Pancreatic ductal adenocarcinoma
42 41728 10 22854210 23744923 Gain Pancreatic ductal adenocarcinoma
43 44446 10 57203760 58367659 Gain Pancreatic ductal adenocarcinoma
44 44911 10 64846281 66342495 Gain Pancreatic ductal adenocarcinoma
45 45553 10 72143312 73316160 Loss Pancreatic ductal adenocarcinoma
46 45655 10 73316160 74391172 Gain Pancreatic ductal adenocarcinoma
47 45775 10 74391172 75333936 Gain Pancreatic ductal adenocarcinoma
48 45937 10 75333936 76299818 Gain Pancreatic ductal adenocarcinoma
49 46231 10 79273961 80171344 Loss Pancreatic ductal adenocarcinoma
50 46288 10 80171344 81279277 Loss Pancreatic ductal adenocarcinoma

Expression for Pancreatic Ductal Adenocarcinoma

LifeMap Discovery
Genes differentially expressed in tissues of Pancreatic Ductal Adenocarcinoma patients vs. healthy controls: 35 (show top 50) (show all 375)
# Gene Description Tissue Up/Dn Fold Change (log2) P value
1 SYCN syncollin Pancreas - 8.04 0.000
2 GP2 glycoprotein 2 Pancreas - 7.99 0.000
3 ALB albumin Pancreas - 7.95 0.000
4 SERPINI2 serpin family I member 2 Pancreas - 7.95 0.000
5 CELA2B chymotrypsin like elastase 2B Pancreas - 7.74 0.000
6 PNLIPRP1 pancreatic lipase related protein 1 Pancreas - 7.66 0.000
7 PDIA2 protein disulfide isomerase family A member 2 Pancreas - 7.53 0.000
8 SPX spexin hormone Pancreas - 7.53 0.000
9 CTRL chymotrypsin like Pancreas - 7.52 0.000
10 COL10A1 collagen type X alpha 1 chain Pancreas + 7.52 0.000
11 CELP carboxyl ester lipase pseudogene Pancreas - 7.50 0.000
12 COL5A1 collagen type V alpha 1 chain Pancreas + 7.46 0.000
13 SULF1 sulfatase 1 Pancreas + 7.38 0.000
14 CUZD1 CUB and zona pellucida like domains 1 Pancreas - 7.29 0.000
15 POSTN periostin Pancreas + 7.24 0.000
16 COL1A1 collagen type I alpha 1 chain Pancreas + 7.17 0.000
17 AQP8 aquaporin 8 Pancreas - 7.14 0.000
18 CEACAM5 CEA cell adhesion molecule 5 Pancreas + 7.10 0.000
19 COL11A1 collagen type XI alpha 1 chain Pancreas + 7.00 0.000
20 CLPS colipase Pancreas - 6.99 0.000
21 INHBA inhibin subunit beta A Pancreas + 6.95 0.000
22 CPA2 carboxypeptidase A2 Pancreas - 6.88 0.000
23 CTRC chymotrypsin C Pancreas - 6.87 0.000
24 CEACAM6 CEA cell adhesion molecule 6 Pancreas + 6.86 0.000
25 PLA2G1B phospholipase A2 group IB Pancreas - 6.79 0.001
26 COL3A1 collagen type III alpha 1 chain Pancreas + 6.78 0.000
27 SFRP4 secreted frizzled related protein 4 Pancreas + 6.76 0.000
28 CELA3A chymotrypsin like elastase 3A Pancreas - 6.76 0.001
29 GNMT glycine N-methyltransferase Pancreas - 6.74 0.000
30 COL1A2 collagen type I alpha 2 chain Pancreas + 6.72 0.000
31 REG1CP regenerating family member 1 gamma, pseudogene Pancreas - 6.72 0.000
32 S100P S100 calcium binding protein P Pancreas + 6.67 0.000
33 CELA3B chymotrypsin like elastase 3B Pancreas - 6.66 0.001
34 CEL carboxyl ester lipase Pancreas - 6.63 0.001
35 CTHRC1 collagen triple helix repeat containing 1 Pancreas + 6.60 0.000
36 CPA1 carboxypeptidase A1 Pancreas - 6.56 0.001
37 VCAN versican Pancreas + 6.51 0.000
38 TMEM52 transmembrane protein 52 Pancreas - 6.40 0.000
39 REG1B regenerating family member 1 beta Pancreas - 6.35 0.002
40 CTSE cathepsin E Pancreas + 6.30 0.000
41 GLS2 glutaminase 2 Pancreas - 6.28 0.000
42 KLK1 kallikrein 1 Pancreas - 6.26 0.000
43 GJB2 gap junction protein beta 2 Pancreas + 6.24 0.000
44 REG3G regenerating family member 3 gamma Pancreas - 6.17 0.000
45 PLAU plasminogen activator, urokinase Pancreas + 6.15 0.000
46 COL5A2 collagen type V alpha 2 chain Pancreas + 6.13 0.000
47 SLC39A5 solute carrier family 39 member 5 Pancreas - 6.09 0.000
48 ERP27 endoplasmic reticulum protein 27 Pancreas - 6.07 0.000
49 SEMA3C semaphorin 3C Pancreas + 6.00 0.000
50 PNLIP pancreatic lipase Pancreas - 5.94 0.004
Search GEO for disease gene expression data for Pancreatic Ductal Adenocarcinoma.

Pathways for Pancreatic Ductal Adenocarcinoma

Pathways related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 9.7 UCA1 HOTAIR

GO Terms for Pancreatic Ductal Adenocarcinoma

Biological processes related to Pancreatic Ductal Adenocarcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of activated T cell proliferation GO:0042104 9.4 MIR21 MIR155
2 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.37 MIR21 H19
3 positive regulation of cardiac muscle hypertrophy GO:0010613 9.32 MIR21 MIR155
4 negative regulation of innate immune response GO:0045824 9.26 MIR21 MIR155
5 positive regulation of reactive oxygen species biosynthetic process GO:1903428 9.16 MIR155 H19
6 negative regulation of regulatory T cell differentiation GO:0045590 8.96 MIR21 MIR155
7 negative regulation of superoxide dismutase activity GO:1901670 8.62 MIR21 H19

Sources for Pancreatic Ductal Adenocarcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....